Literature DB >> 6643405

Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report.

G L Stimmel, I R Falloon.   

Abstract

Marked worsening of adverse effects and increased chlorpromazine plasma levels were observed in a 25-year-old schizophrenic outpatient who abruptly stopped smoking cigarettes. Presence and severity of adverse effects and chlorpromazine plasma levels correlated directly with tobacco smoking over a 16-month period.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6643405

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


  10 in total

Review 1.  Drug interactions between herbal and prescription medicines.

Authors:  Elizabeth M Williamson
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics.

Authors:  L G Miller
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

Review 3.  Drug interactions with tobacco smoking. An update.

Authors:  S Zevin; N L Benowitz
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

Review 4.  Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

Authors:  H D Desai; J Seabolt; M W Jann
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 5.  Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs.

Authors:  J Fang; J W Gorrod
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

6.  Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.

Authors:  M W Jann; S R Saklad; L Ereshefsky; A L Richards; C A Harrington; C M Davis
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 7.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

8.  Smoking and body weight influence the clearance of chlorpromazine.

Authors:  M Chetty; R Miller; S V Moodley
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 9.  A clinical approach to help psychiatric patients with smoking cessation.

Authors:  G W Dalack; A H Glassman
Journal:  Psychiatr Q       Date:  1992

Review 10.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.